GKL-006 Injection

GKL-006 Injection (GKL-006) is an autologous iNKT cell therapy from Beijing Gene Key Life Technology. An iNKT (invariant natural killer T) cell therapy: the patient's own iNKT cells are collected, grown in the laboratory and infused back, per the registry. Its furthest stage is phase 2, for unresectable hepatocellular carcinoma and advanced pancreatic ductal adenocarcinoma. ClinicalTrials.gov registers it in 4 studies linked below. Registry only: NCT07209813 phase 2 recruiting (HCC, with TACE); NCT07777211 phase 1/2 active not recruiting (pancreatic, with nab-paclitaxel and gemcitabine); NCT07713290 phase 1 active not recruiting (HCC, with TACE); NCT07845266 phase 1 completed (HCC, with TACE). Whether it works in people has not been established unless a trial below reports it.